Moderna Therapeutics has been launched with a $40 million round of financing led by Cambridge-based Flagship Ventures, after 18 months of being incubated at Flagship VentureLabs. The company has a novel technology platform based on technology licensed from Harvard University, that the company’s CEO said will enable the discovery of hundreds of new treatments for previously incurable diseases.